Team 3 – PhD Theses

“Welcome to Early stages of Parkinson’s disease”

MAP2/TGN-46/DAPI

Primary cortical neuron with staining for MAP2, TGN-46 and DAPI.

PPP2CA LRRK2

Primary cortical neuron with staining for PPP2CA and LRRK2.

CRISPR/Cas9

CRISPR/Cas9 technology used in the lab to silence or activate transcription in human cells: dCas9-mediated transcriptional modulation of phosphatases.
(A) dCas9 fused to effector domains can serve as an RNA-guided DNA-binding protein to target any protein to any DNA sequence. The effectors used with the catalytically inactive Cas9 (dCas9) are KRAB fusion protein to repress (CRISPRi) or the VP64 fusion protein to activate (CRISPRa) expression has shown on the picture.
(B) Stable suppression and overexpression of PPP1R1B by dCas9-KRAB or dCas9-VP64 in SH-SY5Y cells respectively. Cells stably expressing dCas9-KRAB or VP64 were infected with lentivirus constructs expressing a negative control sgRNA or two different sgRNAs targeting PPP1R1B.

Équipe Étapes précoces dans la maladie de Parkinson
You are here: Home > Early stages of Parkinson's disease > PhD theses

EARLY STAGES OF PARKINSON'S DISEASE

PhD Theses

  • DEBROUCKER Amélie, PhD
  • MUTEZ Eugénie, PhD
  • KREISLER Alexandre PhD
  • LARVOR Lydie, PhD
  • NKILIZA Aurore, PhD
  • SIMONIN Clémence, PhD
  • STIEVENARD Aleçia, PhD